A Randomized Trial of the Effect of Escitalopram Versus Placebo on Cognitive Function in Healthy First-degree Relatives of Patients with Depression

Overview

Journal Ther Adv Psychopharmacol

Specialty Psychiatry

Date 2013 Aug 29

PMID 23983938

Citations 4

Authors

Ulla Knorr

Maj Vinberg

Anders Gade

Per Winkel

Christian Gluud

Jorn Wetterslev

Ulrik Gether

Lars Kessing

Affiliations

Soon will be listed here.

Abstract

The effect of selective serotonin receptor inhibitors (SSRIs) on healthy individuals remains unclear. The aim of the trial was to evaluate the effect of the SSRI escitalopram on cognitive function in healthy first-degree relatives of patients with major depressive disorder (FDRs). A total of 80 FDRs were randomized to escitalopram (10 mg/day) (n = 41) versus placebo (n = 39) for 4 weeks. Neuropsychological tests and ratings of mood were applied at entry (T0) and at 4 weeks (T4). The main outcome measure was calculated as the change (T4-T0) in a general cognition score, which was the standardized mean of 13 test measures. Mean change in the general cognition score was not significantly increased with escitalopram compared with placebo (p = 0.37) or for any of the specific tests. In univariate analyses no statistically significant correlations were found between change in the general cognitive score and the variables age, sex, Hamilton depression score 17 items, Danish Adult Reading Test-45, and plasma escitalopram levels, respectively. These results suggest that treatment with escitalopram does not improve or impair cognitive function in FDRs. Improvement in cognitive function following treatment of depressed patients with SSRIs seems to be related to the effects on depressive symptoms rather than to a direct effect of the SSRI.

Citing Articles

Effect of cognitive retraining treatment in mild to moderate depressive disorders.

Gupta A, Kumari S Psicol Reflex Crit. 2023; 36(1):28.

PMID: 37721578 PMC: 10507003. DOI: 10.1186/s41155-023-00269-9.

Comparing the effects of four common drug classes on the progression of mild cognitive impairment to dementia using electronic health records.

Xu J, Wang F, Zang C, Zhang H, Niotis K, Liberman A Sci Rep. 2023; 13(1):8102.

PMID: 37208478 PMC: 10199021. DOI: 10.1038/s41598-023-35258-6.

Serotonin and brain function: a tale of two receptors.

Carhart-Harris R, Nutt D J Psychopharmacol. 2017; 31(9):1091-1120.

PMID: 28858536 PMC: 5606297. DOI: 10.1177/0269881117725915.

Effect of chronic escitalopram versus placebo on personality traits in healthy first-degree relatives of patients with depression: a randomized trial.

Knorr U, Vinberg M, Mortensen E, Winkel P, Gluud C, Wetterslev J PLoS One. 2012; 7(2):e31980.

PMID: 22393376 PMC: 3290539. DOI: 10.1371/journal.pone.0031980.

References

Beck A, Ward C, Mendelson M, Mock J, ERBAUGH J . An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4:561-71. DOI: 10.1001/archpsyc.1961.01710120031004. View

Murphy S, Yiend J, Lester K, Cowen P, Harmer C . Short-term serotonergic but not noradrenergic antidepressant administration reduces attentional vigilance to threat in healthy volunteers. Int J Neuropsychopharmacol. 2008; 12(2):169-79. DOI: 10.1017/S1461145708009164. View

Knorr U, Kessing L . The effect of selective serotonin reuptake inhibitors in healthy subjects. A systematic review. Nord J Psychiatry. 2010; 64(3):153-63. DOI: 10.3109/08039480903511381. View

Siepmann M, Grossmann J, Muck-Weymann M, Kirch W . Effects of sertraline on autonomic and cognitive functions in healthy volunteers. Psychopharmacology (Berl). 2003; 168(3):293-8. DOI: 10.1007/s00213-003-1448-4. View

Sogaard B, Mengel H, Rao N, Larsen F . The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol. 2005; 45(12):1400-6. DOI: 10.1177/0091270005280860. View

Wingen M, Bothmer J, Langer S, Ramaekers J . Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry. 2005; 66(4):436-43. DOI: 10.4088/jcp.v66n0405. View

SCHMITT J, Kruizinga M, Riedel W . Non-serotonergic pharmacological profiles and associated cognitive effects of serotonin reuptake inhibitors. J Psychopharmacol. 2001; 15(3):173-9. DOI: 10.1177/026988110101500304. View

Lindstrom E, Lewander T, Malm U, Malt U, Lublin H, Ahlfors U . Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord J Psychiatry. 2002; 55 Suppl 44:5-69. DOI: 10.1080/080394801317084428. View

Harmer C, Shelley N, Cowen P, Goodwin G . Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry. 2004; 161(7):1256-63. DOI: 10.1176/appi.ajp.161.7.1256. View

10.

Knutson B, Cole S, Wolkowitz O, Reus V, Chan T, Moore E . Serotonergic intervention increases affiliative behavior in humans. Ann N Y Acad Sci. 1997; 807:492-3. DOI: 10.1111/j.1749-6632.1997.tb51948.x. View

11.

Wing J, Babor T, Brugha T, Burke J, Cooper J, GIEL R . SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry. 1990; 47(6):589-93. DOI: 10.1001/archpsyc.1990.01810180089012. View

12.

Roth M, Tym E, Mountjoy C, Huppert F, Hendrie H, Verma S . CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry. 1986; 149:698-709. DOI: 10.1192/bjp.149.6.698. View

13.

Bech P, Kastrup M, Rafaelsen O . Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand Suppl. 1986; 326:1-37. View

14.

Knorr U, Vinberg M, Klose M, Feldt-Rasmussen U, Hilsted L, Gade A . Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram.... Trials. 2009; 10:66. PMC: 2731751. DOI: 10.1186/1745-6215-10-66. View

15.

Austin M, Mitchell P, Goodwin G . Cognitive deficits in depression: possible implications for functional neuropathology. Br J Psychiatry. 2001; 178:200-6. DOI: 10.1192/bjp.178.3.200. View

16.

Drueke B, Baetz J, Boecker M, Moeller O, Hiemke C, Grunder G . Differential effects of escitalopram on attention: a placebo-controlled, double-blind cross-over study. Psychopharmacology (Berl). 2009; 207(2):213-23. DOI: 10.1007/s00213-009-1649-6. View

17.

Turner E, Matthews A, Linardatos E, Tell R, Rosenthal R . Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008; 358(3):252-60. DOI: 10.1056/NEJMsa065779. View

18.

Schmitt J, Riedel W, Vuurman E, Kruizinga M, Ramaekers J . Modulation of the critical flicker fusion effects of serotonin reuptake inhibitors by concomitant pupillary changes. Psychopharmacology (Berl). 2002; 160(4):381-6. DOI: 10.1007/s00213-001-0993-y. View

19.

Gotzsche P . Blinding during data analysis and writing of manuscripts. Control Clin Trials. 1996; 17(4):285-90; discussion 290-3. DOI: 10.1016/0197-2456(95)00263-4. View

20.

Ramaekers J, Muntjewerff N, OHanlon J . A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance. Br J Clin Pharmacol. 1995; 39(4):397-404. PMC: 1365127. DOI: 10.1111/j.1365-2125.1995.tb04468.x. View